WCTC has a formal policy regarding the need for authors and presenters to inform Annual Meeting attendees of any potential Conflict of Interest (COI). A COI includes, but is not limited to, employment, ownership of stock, membership on a standing advisory council or committee, or being on the board of directors or publicly associated with a company or its products. Other potential areas of real or perceived conflict of interest could include receiving honoraria, consulting fees, or grants.
Grants: ARC Foundation for Cancer Research, ELIOS GRANT
Consultant: Eisai, Exelixis, Loxo, Bayer, Ipsen
Grants to Institution: JM is the President of the IRCAD Institute, which is partly funded by Karl Storz and Medtronic; Stock Shareholder: Visible Patient Company
Commercial interest/company: Eisai, Lilly, BluePrint Pharmaceuticals, MJH Life Sciences, Exelixis. Honoraria received for speaking/education. This does not relate to content of presentation
A. Visible Patient 1. Financial relationship with Visible Patient company. 2. I receive a monthly salary. 3. I am the president of that company. B. Ethicon/Johnson & Johnson 1. Commercial interest 2. Marketing and distributing of Visible Patient Solution 3. I am president of Visible Patient, a Partner of Ethicon
R Michael Tuttle
Grants: Research support to MSKCC Elesta (clinical trial of laser ablation of papillary microcarcinoma)
Grants: FAPERJ, CNPq; Research Support: FAPERJ, Bayer; Consultant: Exilisis, Lilly, Sanofi-Genzyme and Merck
Consultant: Bayer Healthcare, Blueprint Medicines, Eli Lilly, Eisai, Exelixis, Genentech USA, Loxo Oncolology, Merck; Honoraria from Iovance Biotherapeutics and PDS Biotechnolgy Corporation for serving on data safety monitoring committee
Consultant: GlaxoSmithKline, Medtronic Canada, Sanofi Genzyme; Stock Shareholder: Proteocyte Diagnostics Inc.